SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery

NYSE - LSE

CMSC	-0.09%	21.29	$
RELX	0.66%	36.54	$
JRI	-0.4%	12.35	$
BCE	0.26%	23.46	$
CMSD	0%	21.18	$
BCC	-0.03%	78.75	$
RIO	-1.43%	103.3	$
BTI	-0.27%	56.13	$
AZN	-1.12%	162.7	$
GSK	1.08%	50.82	$
VOD	1%	16.04	$
NGG	-0.1%	79.35	$
RBGPF	0.11%	70.77	$
BP	-0.45%	42.15	$
RYCEF	-1.22%	20.5	$

SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery

BOULEVARD 06.11.2025

CHINO HILLS, CALIFORNIA / ACCESS Newswire / November 6, 2025 / SOHM, Inc. (OTCID:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, a leader in Gene Editing and Cell Engineering is pleased to announced the release of a technical white paper describing ABBIE, a Cas9-guided integrase platform that enables donor-DNA integration without double-strand breaks or viral vectors. Using ABBIE, the team established SKOV3-GYS1, an ovarian cancer cell line with stable overexpression of glycogen synthase 1 (GYS1) to support drug-discovery applications focused on glycogen metabolism.

Text size:

Highlights from the white paper

Non-viral, DSB-free integration: ABBIE employs a dCas9-integrase fusion to guide targeted, donor-DNA integration while avoiding double-strand breaks and viral delivery.
Functional overexpression achieved: In ABBIE-engineered cells, GYS1 protein levels were ~3× those of parental SKOV3 cells, and GYS1 catalytic activity exceeded 5× parental levels.
Genomic characterization: Following selection, bulk populations exhibited stable donor integration. Whole-genome sequencing of the highest-expressing clone revealed a single integration event at an intergenic locus.
Targeting note & ongoing work: While ABBIE is guide-directed, the exact insertion coordinates can diverge from the canonical CRISPR-Cas9 target. Ongoing studies are refining target-selection rules and determinants of integration site choice to further improve precision and reproducibility.

Research and development significance

GYS1 plays a central role in glycogen metabolism and has been implicated in tumor survival under stress conditions. The SKOV3-GYS1 line offers a robust in-vitro platform for mechanistic studies and for screening GYS1-targeting small molecules and other metabolic modulators. More broadly, ABBIE's non-viral, DSB-free approach may help expand knock-in strategies for cell-engineering and model development.

Partnership opportunities

SOHM welcomes strategic partnerships to accelerate assay development, screening campaigns, and platform optimization using ABBIE-engineered models. Interested parties are invited to contact SOHM.

White paper: Articles and Publications - SOHM Inc.

https://sohm.com/abbie-and-the-future-of-cancer-research/

About SOHM, Inc.:

SOHM is a biopharmaceutical company dedicated to developing and commercializing gene editing technologies for research, synthetic biology, and therapeutic applications. With a focus on precision medicine, SOHM aims to revolutionize the treatment of genetic diseases by providing safe, efficient, and targeted gene editing solutions. Through strategic collaborations and groundbreaking research, SOHM is at the forefront of advancing the field of gene therapy. SOHM strives to transform the landscape of genome editing and improve the quality of life through scientific discovery.

For further information regarding this announcement or to explore potential collaborations, please contact:

SOHM, Inc.:
Name: Baron Night, CEO/Dr. David Aguilar, COO
Email: [email protected]
Phone: (714) 522-6700

Safe Harbor Statement:

This news release contains "forward-looking statements," which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development-stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report for the most recent fiscal year and our quarterly reports uploaded from time to time on OTCMarkets.com.

SOURCE: SOHM, Inc

View the original press release on ACCESS Newswire

B.Torres--AT

Arizona Tribune - SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery

SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery

Featured

UN, Nepal warn of climate threat after deadly floods

Rescuers dig into tunnel as missing toll from Nepal, China flood nears 3,000

Kanye West Does Not Address Milo Yiannopoulos Detention During New Orleans Concert

Taylor Swift Donation Supports Connecticut Mother Recovering From Serious Roadside Injuries